# Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

> **NCT03263572** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 90 (estimated)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Lymphoblastic Leukemia
- BCR-ABL1 Fusion Protein Expression
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive
- Recurrent Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- t(9;22)

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT03263572
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-29
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263572, "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03263572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*